<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-111594</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Acute Hepatitis C in a Patient Receiving Etanercept</dc:title>
<dc:description xml:lang="en">According to the literature, the use of tumor necrosis factor (TNF) inhibitors in patients with chronic hepatitis C infection is safe and effective. There have been no reports, however, of primary infection with the hepatitis C virus during treatment with a biologic agent. We report the case of a patient with long-standing moderate to severe psoriasis who developed acute hepatitis C while being treated with etanercept. Biologic therapy was continued and the infection was successfully treated with pegylated interferon, which achieved a sustained virologic response. Etanercept did not have a negative impact on disease outcome or on response to antiviral treatment (AU)</dc:description>
<dc:creator>Armengot-Carbó, M</dc:creator>
<dc:creator>Velasco, M</dc:creator>
<dc:creator>Gimeno, E</dc:creator>
<dc:creator>Giner, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El uso de agentes bloqueadores del factor de necrosis tumoral alfa (anti-TNF&amp;#945;) en pacientes con hepatitis C crónica ha sido descrito en la literatura en su conjunto como seguro y eficaz. Sin embargo, no se han descrito hasta la fecha casos de primoinfección por el virus de la hepatitis C ocurridos durante el tratamiento con un biológico. Presentamos un paciente con psoriasis moderada-severa de larga evolución que, estando en tratamiento con etanercept, sufrió una hepatitis C aguda. Sin suspender el fármaco anti-TNF&amp;#945; recibió tratamiento con interferón pegilado, con respuesta virológica sostenida. Etanercept no interfirió de forma negativa en la evolución de la enfermedad ni en la respuesta al tratamiento antiviral (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;104(3): 239-241, abr. 2013. ilus</dc:source>
<dc:identifier>ibc-111594</dc:identifier>
<dc:title xml:lang="es">Hepatitis C aguda en un paciente en tratamiento con etanercept</dc:title>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d29591^s22006</dc:subject>
<dc:subject>^d30351^s22032</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12002^s22016</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12002^s22012</dc:subject>
<dc:subject>^d12002^s22032</dc:subject>
<dc:subject>^d29469^s22073</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d30351^s22057</dc:subject>
<dc:subject>^d30351^s22012</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d30351^s22036</dc:subject>
<dc:subject>^d30351^s22016</dc:subject>
<dc:subject>^d25575^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201304</dc:date>
</metadata>
</record>
</ibecs-document>
